Alpha 2.0
Login Register
» Articles » PMID: 34568744

Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 MRNA Vaccine

Overview
Journal TH Open
Publisher Thieme
Date 2021 Sep 27
PMID 34568744
Citations 8
Authors
Katerina Pavenski
Affiliations
Soon will be listed here.
Abstract

An 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroids and rituximab and subsequently recovered. This case report highlights the need to monitor patients with iTTP following vaccination.

Citing Articles

Thrombosis post-mRNA-based SARS-CoV-2 vaccination (BNT162b2) - Time to think beyond thrombosis with thrombocytopenia syndrome (TTS).

Yousaf Z, Ata F, Mohammed Hammamy R Thromb Update. 2024; 7:100104.

PMID: 38620755 PMC: 9013693. DOI: 10.1016/j.tru.2022.100104.

Thrombotic thrombocytopenic purpura developed after pegylated interferon treatment for hepatitis B infection.

Mei S, Feng Y, Cui L, Chen J, Mao Z, Zhao X BMC Nephrol. 2022; 23(1):400.

PMID: 36513992 PMC: 9745695. DOI: 10.1186/s12882-022-03034-9.

Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection.

Fang F, Tse B, Pavenski K BMJ Case Rep. 2022; 15(7).

PMID: 35902184 PMC: 9341178. DOI: 10.1136/bcr-2021-247524.

Acquired Thrombotic Thrombocytopenic Purpura Following Inactivated COVID-19 Vaccines: Two Case Reports and a Short Literature Review.

Ben Saida I, Maatouk I, Toumi R, Bouslama E, Ben Ismail H, Ben Salem C Vaccines (Basel). 2022; 10(7).

PMID: 35891176 PMC: 9319973. DOI: 10.3390/vaccines10071012.

Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature.

Buetler V, Agbariah N, Schild D, Liechti F, Wieland A, Andina N Front Med (Lausanne). 2022; 9:890661.

PMID: 35655852 PMC: 9152022. DOI: 10.3389/fmed.2022.890661.

References
1.
Yavasoglu I . Vaccination and Thrombotic Thrombocytopenic Purpura. Turk J Haematol. 2020; 37(3):218-219. PMC: 7463209. DOI: 10.4274/tjh.galenos.2020.2020.0060. View
2.
Cuker A, Cataland S, Coppo P, Rubia J, Friedman K, George J . Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021; 137(14):1855-1861. DOI: 10.1182/blood.2020009150. View
3.
Yocum A, Simon E . Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination. Am J Emerg Med. 2021; 49:441.e3-441.e4. PMC: 8095021. DOI: 10.1016/j.ajem.2021.05.001. View
4.
Franchini M, Liumbruno G, Pezzo M . COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol. 2021; 107(2):173-180. PMC: 8239516. DOI: 10.1111/ejh.13665. View
5.
Sissa C, Al-Khaffaf A, Frattini F, Gaiardoni R, Mimiola E, Montorsi P . Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine. Transfus Apher Sci. 2021; 60(4):103145. PMC: 8051010. DOI: 10.1016/j.transci.2021.103145. View